Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients

European Journal of Cancer

Volumn 47, Issue 14, 2011, Pages 2084-2090

  Kong, Xiangnan ^a   Moran, Meena S ^b   Zhang, Ning ^a   Haffty, Bruce ^c   Yang, Qifeng ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Meta analysis; Neoadjuvant chemotherapy; Pathological complete response; Prognosis; Prognostic indicator

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALOPECIA; ANEMIA; BREAST CANCER; CARDIOTOXICITY; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PREOPERATIVE PERIOD; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 80052546951     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.014     Document Type: Article

References (29)

1. W. He Observation of therapeutic effectiveness of neoadjuvant chemotherapy in breast cancer Chinese Community Doctors 24 12 2010 79
2. M. De Lena, R. Zucali, G. Viganotti, P. Valagussa, and G. Bonadonna Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer Cancer Chemother Pharmacol 1 1 1978 53 59 (Pubitemid 9025112)
3. G.M. Beasley, and J.A. Olson Jr What's new in neoadjuvant therapy for breast cancer? Adv Surg 44 2010 199 228
4. B. Fisher, A. Brown, and E. Mamounas Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 7 1997 2483 2493 (Pubitemid 27289876)
5. B. Fisher, J. Bryant, and N. Wolmark Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 1998 2672 2685 (Pubitemid 28363030)
6. L. Gianni, J. Baselga, and W. Eiermann Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy Clin Cancer Res 11 24 Pt 1 2005 8715 8721 (Pubitemid 43005921)
7. N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 2001 96 102
8. B. Fisher, E. Saffer, C. Rudock, J. Coyle, and N. Gunduz Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice Cancer Res 49 8 1989 2002 2004 (Pubitemid 19106504)
9. H.D. Bear, S. Anderson, and R.E. Smith Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 13 2006 2019 2027 (Pubitemid 46622110)
10. F. Andre, C. Mazouni, and C. Liedtke HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Res Treat 108 2 2008 183 190 (Pubitemid 351311360)
11. Y. Eralp, T.L. Smith, and K. Altundag Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger J Cancer Res Clin Oncol 135 1 2009 141 148
12. A.H. Honkoop, P.J. van Diest, and J.S. de Jong Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer Br J Cancer 77 4 1998 621 626 (Pubitemid 28059470)
13. H.M. Kuerer, L.A. Newman, and T.L. Smith Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 1999 460 469 (Pubitemid 29075229)
14. V. Dieras, P. Fumoleau, and G. Romieu Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer J Clin Oncol 22 24 2004 4958 4965 (Pubitemid 46638621)
15. A.A. Ezzat, E.M. Ibrahim, and D.S. Ajarim Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients Br J Cancer 90 5 2004 968 974 (Pubitemid 38495813)
16. A.E. Ring, I.E. Smith, S. Ashley, L.G. Fulford, and S.R. Lakhani Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 12 2004 2012 2017 (Pubitemid 40128767)
17. S.C. Abrial, F. Penault-Llorca, and R. Delva High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer Breast Cancer Res Treat 94 3 2005 255 263 (Pubitemid 41677630)
18. M. Toi, S. Nakamura, and K. Kuroi Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival Breast Cancer Res Treat 110 3 2008 531 539 (Pubitemid 351962591)
19. O. Huang, C. Chen, and J. Wu Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months BMC Cancer 9 2009 375
20. G. Frasci, P. Comella, and M. Rinaldo Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer Ann Oncol 20 7 2009 1185 1192
21. W.M. Sikov, D.S. Dizon, and R. Strenger Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study J Clin Oncol 27 28 2009 4693 4700
22. S.Y. Jung, S.K. Kim, and B.H. Nam Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy Ann Surg Oncol 17 1 2010 247 253
23. H.R. Chang, J. Glaspy, and M.A. Allison Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment Cancer 116 18 2010 4227 4237
24. T.A. Al-Tweigeri, D.S. Ajarim, and A.A. Alsayed Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer Med Oncol 27 3 2010 571 577
25. T.A. Buchholz, C.D. Lehman, and J.R. Harris Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference J Clin Oncol 26 5 2008 791 797 (Pubitemid 351265334)
26. S.D. Heys, T. Sarkar, and A.W. Hutcheon Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival Breast Cancer Res Treat 90 2 2005 169 185 (Pubitemid 40568900)
27. G. von Minckwitz, G. Raab, and A. Caputo Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 12 2005 2676 2685 (Pubitemid 46179457)
28. M. Untch, V. Mobus, and W. Kuhn Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer J Clin Oncol 27 18 2009 2938 2945
29. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 2008 1275 1281